Therapeutic potential of the IL-3-IL-5-GM-CSF common beta receptor to treat upper and lower allergic airway

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/510803

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This research aims to develop new treatments for allergic diseases such as asthma and allergic rhinitis, which remain significant public health problems in Australia. We will develop new therapies with the potential to completely suppress acute and chronic allergic disease targeting a common receptor protein that controls multiple facets of allergic inflammation. We will test antibodies intended to treat human asthma using a novel mouse strain expressing the human form of this receptor.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2012

Funding Scheme: Early Career Fellowships

Funding Amount: $150,442.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Anaesthesiology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

airway inflammation | asthma | chronic inflammation | respiratory allergy

Related Links